Announcements
Removal of Component(s) – EIDX, PRVL
January 21, 2021
Effective at the market close on Thursday January 21, EIDX and PRVL will be removed from the LifeSci Biotechnology Clinical Trials Index and their values will be redistributed to the remaining index components based on their weights.
- On October 5, 2020, Eidos agreed to be acquired by BridgeBio for a combination of cash and stock.
- On December 15, 2020, Prevail agreed to be acquired by Eli Lilly for $26.50/share in cash.
